Financial Performance - AbbVie Inc. reported second-quarter 2025 adjusted EPS of $2.97, exceeding the Zacks Consensus Estimate of $2.89 and the company's guidance of $2.84-$2.88, with earnings rising 12.1% year over year [1] - Revenues for the quarter reached $15.42 billion, surpassing the Zacks Consensus Estimate of $15.07 billion, with a year-over-year increase of 6.6% on a reported basis and 6.5% on an operational basis [2] Key Drug Performance - Sales of Rinvoq totaled $2.03 billion, up 41.2%, driven by market share gains and recent label expansion [4] - Skyrizi generated $4.42 billion in sales, reflecting a 61.8% increase, attributed to strong volume growth and market share gains [5] - Humira experienced a significant sales decline of 58.2% to $1.18 billion, with U.S. sales down 66% to $802 million due to loss of exclusivity [6][7] - Neuroscience portfolio sales increased 24% to $2.68 billion, driven by higher sales of Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta [8] Oncology and Other Drug Sales - Oncology franchise sales rose 2.4% to $1.68 billion, supported by newer drugs like Epkinly and Elahere, despite a decline in Imbruvica sales [10][11] - Venclexta generated revenues of $691 million, reflecting 8.3% growth, while Elahere sales rose 23.7% to $159 million, although it missed expectations [13] Cost and Guidance - Adjusted SG&A expenses decreased 2.3% year over year to $3.24 billion, while adjusted R&D expenses increased 10.3% to $2.12 billion [16] - AbbVie raised its full-year 2025 EPS guidance to a range of $11.88-$12.08, up from the previous range of $11.67-$11.87 [17] Market Reaction and Strategic Moves - AbbVie shares rose over 5% in pre-market trading following the upward revision in guidance, with a year-to-date stock gain of about 7% compared to the industry's 4% decline [20] - The company continues to invest in its future pipeline through strategic collaborations, including a licensing deal for an investigational trispecific antibody and interest in acquiring Gilgamesh Pharmaceuticals [22]

Financial Data and Key Metrics Changes - AbbVie reported adjusted earnings per share of $2.97, which is $0.11 above the guidance midpoint [6] - Total net revenues were $15.4 billion, exceeding expectations by over $400 million, reflecting a 6.5% operational growth [7][36] - The company raised its full-year revenue guidance to $60.5 billion, an increase of $800 million, and adjusted EPS guidance to between $11.88 and $12.08 [8][37] Business Line Data and Key Metrics Changes - Immunology revenues exceeded $7.6 billion, with SKYRIZI global sales at $4.4 billion, up 61.8% operationally [10][11] - RINVOQ global sales reached $2 billion, up 41.2% operationally, with strong uptake in IBD [12][13] - Neuroscience revenues were approximately $2.7 billion, up 24% operationally, driven by Vraylar and UBRELVY [20] - Oncology revenues were nearly $1.7 billion, with IMBRUVICA sales down 9.5% and VENCLEXTA sales up 8.3% [16][17] - Aesthetics revenues were nearly $1.3 billion, down 8% operationally, impacted by economic challenges [18] Market Data and Key Metrics Changes - SKYRIZI continues to capture robust market share in psoriatic disease, leading in the US across all lines of therapy [10][11] - HUMIRA global sales were over $1.1 billion, down 58.2% due to biosimilar competition [15] - The aesthetics market is performing below historical levels, with economic challenges affecting consumer sentiment [18][19] Company Strategy and Development Direction - AbbVie is focused on advancing its pipeline and strategic transactions to support long-term growth, with over 30 business development transactions executed since last year [9] - The company is enhancing its immunology pipeline with innovative therapies and technologies, including the acquisition of Capstan Therapeutics [26][27] - AbbVie aims to leverage its global aesthetics commercial footprint to sell obesity drugs in the future [72][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong outlook for 2025 and beyond, driven by the performance of SKYRIZI and RINVOQ [10][41] - The company is well-positioned to manage potential impacts from tariffs and is investing in US manufacturing capacity [56] - Management highlighted the importance of external innovation and strategic investments to drive growth in the next decade [66] Other Important Information - AbbVie announced impressive Phase III results for RINVOQ in alopecia areata, indicating significant commercial potential [24][97] - The company is actively working to stabilize and grow the dermal filler market amid economic challenges [99] Q&A Session Summary Question: Impact of Stellara biosimilar on SKYRIZI and RINVOQ - Management noted that while there may be some impact, the core momentum for SKYRIZI and RINVOQ is driven by outstanding data and breadth of indications [44][46] Question: Confidence in SKYRIZI and RINVOQ long-term guidance - Management indicated strong performance and momentum, with updates to long-term guidance expected at appropriate times [52][54] Question: Commercial opportunity for alopecia areata - Management highlighted that the new indications for RINVOQ could add approximately $2 billion to peak year sales, with significant potential for momentum [97] Question: Impact of GLP-1s on aesthetics - Management stated that the overall effect is net neutral, with some potential tailwinds for dermal fillers due to patient concerns about facial aesthetics [90]

Financial Data and Key Metrics Changes - Adjusted earnings per share (EPS) for the second quarter was $2.97, exceeding guidance by $0.11 [5][34] - Total net revenues reached $15.4 billion, surpassing expectations by over $400 million, reflecting a 6.5% operational growth [6][34] - Full-year revenue guidance raised to $60.5 billion, an increase of $800 million, with a total increase of $1.5 billion since the start of the year [6][35] - Adjusted EPS guidance for the full year increased by $0.21, now expected between $11.88 and $12.08 [7][35] Business Line Data and Key Metrics Changes - Immunology revenues exceeded $7.6 billion, with SKYRIZI global sales at $4.4 billion, up 61.8% operationally [10][11] - RINVOQ global sales reached $2 billion, reflecting a 41.2% operational growth [12][13] - Neuroscience revenues were approximately $2.7 billion, up 24% operationally, driven by Vraylar and UBRELVY [19][20] - Oncology revenues were nearly $1.7 billion, with IMBRUVICA sales down 9.5% and VENCLEXTA sales up 8.3% [15][16] - Aesthetics revenues were nearly $1.3 billion, down 8% operationally, impacted by economic challenges [17][18] Market Data and Key Metrics Changes - SKYRIZI continues to gain market share in psoriatic disease, with leadership in psoriasis therapy lines [10][11] - RINVOQ is capturing significant patient share in IBD, with strong uptake in ulcerative colitis and Crohn's disease [12][13] - HUMIRA sales declined to over $1.1 billion, down 58.2% due to biosimilar competition [14] - The aesthetics market is underperforming historical levels, with economic challenges affecting consumer sentiment [18][19] Company Strategy and Development Direction - The company is focused on advancing its pipeline and strategic transactions to support long-term growth [5][9] - Recent acquisitions include Gubra for obesity treatment and KapStan Therapeutics for CAR T platform [8][9] - The company aims to enhance its immunology pipeline with innovative therapies and technologies [25][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong outlook for 2025 and beyond, supported by robust performance across key products [10][38] - The company is well-positioned to navigate economic challenges and capitalize on growth opportunities in various therapeutic areas [19][38] Other Important Information - The company has executed over 30 business development transactions since the beginning of the previous year [8] - Regulatory submissions for new therapies are anticipated, including RINVOQ for alopecia areata and vitiligo [24][25] Q&A Session Summary Question: Impact of Stellara biosimilar on SKYRIZI and RINVOQ - Management noted that while there may be some impact, the core momentum for SKYRIZI and RINVOQ is driven by strong data and physician connections [41][42] Question: Confidence in SKYRIZI and RINVOQ long-term guidance - Management indicated that they are tracking well against long-term guidance and will update it at the appropriate time [47][48] Question: Leveraging global aesthetics footprint for obesity drugs - The company sees a strong opportunity to integrate obesity treatments into its aesthetics practices, capitalizing on existing patient flow [66][68] Question: Status of anti-amyloid monoclonal antibody - The company is evaluating the potential for a registrational trial based on imaging as an endpoint, but specific details were not disclosed [94]

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ (Exact name of registrant as specified in its charter) (State or other Jurisdiction (Commission File Number) (IRS Employer Delaware 001-35565 32-0375147 of Incorporation) Identification No.) 1 North Waukegan Road Nor ...

Core Insights - AbbVie reported strong financial results for the second quarter of 2025, with significant growth in its diversified growth platform and pipeline advancements, leading to an increased full-year outlook [2][4][10] Financial Performance - The company achieved second-quarter net revenues of $15.423 billion, reflecting a 6.6% increase on a reported basis and a 6.5% increase on an operational basis [4][5] - Diluted EPS on a GAAP basis was $0.52, a decrease of 32.5%, while adjusted diluted EPS was $2.97, an increase of 12.1% [4][21] - The gross margin for the second quarter was 71.8% on a GAAP basis and 84.4% on an adjusted basis [8] Revenue Breakdown by Portfolio - Immunology portfolio revenues were $7.631 billion, up 9.5% on a reported basis, with Skyrizi and Rinvoq showing significant growth of 62.2% and 41.8%, respectively [4][5][16] - Neuroscience portfolio revenues reached $2.683 billion, an increase of 24.2%, driven by Vraylar and Botox Therapeutic [4][5][16] - Oncology portfolio revenues were $1.676 billion, a modest increase of 2.6%, with Imbruvica experiencing a decline of 9.5% [4][5][16] - Aesthetics portfolio revenues decreased to $1.279 billion, down 8.1%, with Botox Cosmetic and Juvederm also showing declines [4][5][16] Pipeline Developments - AbbVie received FDA approval for Rinvoq as the first oral JAK inhibitor for giant cell arteritis, marking its ninth indication in the U.S. [8] - Positive results were reported from the Phase 3 UP-AA clinical program for Rinvoq in severe alopecia areata, achieving key endpoints [8] - The company announced the acquisition of Capstan Therapeutics, enhancing its capabilities in RNA delivery for cell engineering [8] - Emrelis received accelerated FDA approval for advanced non-small cell lung cancer, expanding AbbVie's oncology treatment options [9] Full-Year Guidance - AbbVie raised its adjusted diluted EPS guidance for 2025 from a range of $11.67 - $11.87 to $11.88 - $12.08, accounting for an unfavorable impact of $0.55 per share related to acquired IPR&D and milestones [10][4]

Company Overview - REGENXBIO Inc. is a biotechnology company focused on gene therapy with a mission to improve lives through its curative potential [3] - The company has been a pioneer in AAV gene therapy since its founding in 2009 [3] - REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne, RGX-121 for MPS II, and RGX-111 for MPS I, in partnership with Nippon Shinyaku [3] - The company is also collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [3] - Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [3] Upcoming Events - REGENXBIO will host a conference call on August 7, 2025, at 8:00 a.m. ET to discuss its financial results for Q2 2025 and operational highlights [1] - Listeners can register for the webcast and analysts can participate in the Q&A session by dialing specific numbers [2] - A replay of the webcast will be available on the company's investor website approximately two hours after the call [2]

Core Insights - AbbVie is set to release its earnings report on July 31, 2025, with current consensus estimates projecting earnings of $2.91 per share on sales of $15.03 billion, compared to $2.65 per share on sales of $14.46 billion in the same quarter last year [3][4] Historical Performance - Over the past five years, AbbVie has experienced a negative one-day return following earnings announcements in 65% of instances, with a median decline of -1.3% and a maximum drop of -7.3% [3][7] - There have been 20 earnings data points recorded over the last five years, with 7 positive and 13 negative one-day returns, resulting in positive returns approximately 35% of the time; this percentage decreases to 17% when considering the last 3 years [7] Financial Metrics - AbbVie currently has a market capitalization of $333 billion, with $57 billion in revenue, $13 billion in operating profits, and a net income of $4.2 billion over the last twelve months [4] Trading Strategies - Traders can analyze historical probabilities and take positions before earnings releases, as well as examine correlations between immediate and medium-term returns post-earnings to adjust positions accordingly [6][8]

Core Insights - AbbVie announced positive topline results from the Phase 3 UP-AA clinical program for upadacitinib (RINVOQ®) in treating severe alopecia areata, showing significant efficacy in hair regrowth [1][3][4] Efficacy Results - In Study 2, 44.6% of patients on 15 mg and 54.3% on 30 mg of upadacitinib achieved 80% or more scalp hair coverage (SALT score ≤ 20) at week 24, compared to 3.4% in the placebo group (p<0.001) [1][3] - Additionally, 36.0% and 47.1% of patients reached 90% or more scalp hair coverage (SALT ≤ 10) with the respective doses, against 1.4% in the placebo group (p<0.001) [1][3] Safety Profile - The safety profile of upadacitinib was consistent with previous studies, with serious adverse events occurring in 1.4% and 2.8% of patients in the 15 mg and 30 mg groups, respectively, and none in the placebo group [1][3] - Common treatment-emergent adverse events included acne, nasopharyngitis, and upper respiratory tract infections, with serious infections reported infrequently [1][3] Study Design - The UP-AA clinical program consists of two pivotal studies (Study 1 and Study 2) with a total of 1,399 participants aged 12 to 64 across 248 sites globally [4][3] - Participants were randomized to receive either upadacitinib or placebo for 24 weeks, followed by an additional 28 weeks for those originally on upadacitinib [4] Future Outlook - Results from the parallel Study 1 are expected in the third quarter of 2025, which will further inform the efficacy and safety of upadacitinib in alopecia areata [3][4]

Core Investment Insights - Great investing often involves holding onto exceptional companies known as blue-chip stocks, which can be challenging to identify in a competitive corporate landscape [1] - Focusing on evergreen industries, such as healthcare, can help in finding reliable investment opportunities [2] Company Summaries AbbVie - AbbVie is a leading biopharmaceutical company with a diverse portfolio addressing over 75 medical conditions, focusing on immunology, neuroscience, oncology, aesthetics, and eye care [4] - The company has successfully replaced its former blockbuster drug, Humira, with new products like Rinvoq and Skyrizi, demonstrating its capacity for innovation [5] - AbbVie is recognized as a Dividend King, having raised its dividend for 53 consecutive years, indicating sustained business growth and strong total investment returns [6] Bristol Myers Squibb - Bristol Myers Squibb is a global biopharmaceutical company with a long history, specializing in oncology, cardiovascular, immunology, neuroscience, and hematology [7] - The company has invested approximately $100 billion in acquisitions to prepare for the loss of patent protection on several top-selling drugs [8] - Analysts project low-single-digit earnings growth in the short to medium term, but the company offers a safe dividend yield of 5.1%, which has been increased for 18 consecutive years [9] Danaher - Danaher is a global leader in life sciences, operating across biotechnology, diagnostics, and life sciences, with over 80% of its revenue coming from recurring sales [10] - The company employs a continuous improvement model known as the Danaher Business System, which has enhanced profit margins and cash flow over time [11] - Danaher has raised its dividend for 10 consecutive years, with analysts estimating annual earnings growth of 9% to 10%, positioning it for solid capital gains and rising dividends [12]

Core Viewpoint - AbbVie has submitted a supplemental New Drug Application (sNDA) to the FDA for a fixed-duration, all-oral combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL), potentially offering a new treatment option with time-limited therapy [1][2]. Group 1: Clinical Trial Results - The submission is based on positive results from the Phase 3 AMPLIFY trial, which demonstrated that the combination of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard chemoimmunotherapy in previously untreated CLL patients [2][3]. - The AMPLIFY trial showed a 35% reduction in the risk of disease progression or death with the fixed-duration combination regimen compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.004) [3]. Group 2: Safety Profile - The safety profile of the VENCLEXTA and acalabrutinib combination is consistent with the known safety profiles of each therapy alone, with common adverse events including neutropenia, hemorrhage, and COVID-19 [3]. - Neutropenia was the most frequent Grade 3 or higher adverse event, occurring in 26.8% of patients, while low rates of tumor lysis syndrome were observed at 0.3% for the combination compared to 3.1% for chemoimmunotherapy [3]. Group 3: Product Information - VENCLEXTA (venetoclax) is a first-in-class medication that selectively inhibits the B-cell lymphoma-2 (BCL-2) protein, which is involved in preventing cancer cell apoptosis [4]. - VENCLEXTA is developed by AbbVie and Roche, and is approved in over 80 countries, including the U.S., with ongoing research into its use across various blood cancers [5]. Group 4: Company Commitment - AbbVie is dedicated to transforming cancer care through a dynamic pipeline of investigational therapies targeting various cancer types, focusing on creating targeted medicines to impede cancer cell reproduction or enable their elimination [23][25].